Skip to main content

For the BIPOC Woman

Your health deserves research that actually centers you.

You have likely been the most symptomatic woman in the room and the least believed.

Hey , I'm glad you're here. This whole section was built for you. Every line is in plain English, every claim has a link to the actual study, and nothing is softened. You can tap any card below to open the full deep-dive when you want it.

The short version, in three sentences:

  • Black women carry the highest fibroid burden in the country.
  • Perimenopause tends to start earlier and hit harder.
  • Black women die from pregnancy-related causes at more than 3 times the rate of White women.

Tell me what's going on. I'll build your briefing.

Tap the symptoms and diagnoses that match your story. Everything below is still here as deeper reading , this just shows you the most relevant evidence first.

Supporting research

The disparities you just read about are not anecdotes. These are the peer-reviewed studies behind every number. Tap any source to verify it on PubMed.

  • Menopausal symptoms and ethnicity: the Study of Women's Health Across the Nation

    SWAN found vasomotor symptoms at perimenopause entry in 46% of Black, 47% of Hispanic, 37% of White, 21% of Chinese American, and 18% of Japanese American women. Vaginal dryness most prevalent in Hispanic women. Symptom experience varies by ethnicity independent of BMI or SES.

  • The association of race, ethnicity, and socioeconomic status on the severity of menopause symptoms: a study of 68,864 women

    Largest published dataset by race/ethnicity (68,864 women over 4 years). Black women significantly more likely to report hot flashes; Latina and mixed-race more likely to report hair/skin changes; Indigenous more likely to report pain with intercourse. Differences persist after controlling for SES.

  • The 2022 Hormone Therapy Position Statement of The North American Menopause Society

    Comprehensive evidence synthesis and clinical position statement on menopausal hormone therapy endorsed by more than 20 medical organisations. Concludes that for healthy women under 60 or within 10 years of menopause onset, the benefits of hormone therapy for vasomotor symptoms outweigh the risks in most cases. The timing hypothesis - that earlier initiation produces more favourable outcomes - is supported by Level 1 evidence. Represents the current gold standard clinical guidance for menopause management.

  • SWHR Menopause Disparities Factsheet: prevalence and health impact across the United States

    Black women reach menopause at average age 49 — two years earlier than the national median — and spend more time in the menopause transition. Hispanic women also reach menopause approximately two years earlier than the national median.

  • Longitudinal Analysis of the Association Between Vasomotor Symptoms and Race/Ethnicity Across the Menopausal Transition: Study of Women's Health Across the Nation

    Black women had the highest rates of hot flashes/night sweats; Chinese and Japanese women had the lowest rates; Hispanic women were intermediate — across the 7-site SWAN cohort of 3,302 midlife women.

  • Duration of Menopausal Vasomotor Symptoms Over the Menopause Transition

    Median VMS duration: Black 10.1 years, Hispanic 8.9, White 6.5, Chinese 5.4, Japanese 4.8. Overall median 7.4 years — far longer than the '2 years' commonly told to patients.

  • Disparities in Reproductive Aging and Midlife Health between Black and White Women: The Study of Women's Health Across the Nation (SWAN)

    Comprehensive SWAN review showing Black women experience earlier menopause, longer VMS, more sleep disruption, and higher depression rates than White women across 25 years of follow-up.

  • High Cumulative Incidence of Uterine Leiomyoma in Black and White Women: Ultrasound Evidence

    Ultrasound screening found >80% of Black women and ~70% of White women had fibroids by age 50; Black women were affected earlier and more severely.

  • Maternal Mortality Rates in the United States, 2022

    US maternal mortality rate 22.3/100k in 2022; Black women 49.5/100k, White women 19.0/100k — a 2.6-fold racial disparity that has persisted for decades.

  • Depressive Symptoms During the Menopausal Transition: The Study of Women's Health Across the Nation (SWAN)

    Late perimenopause associated with ~2.5× higher odds of clinically significant depressive symptoms (CES-D ≥16) vs premenopause in SWAN; Black women had highest absolute depressive symptom burden.

  • Trends in Postpartum Depression by Race, Ethnicity, and Prepregnancy Body Mass Index

    PPD rates rose across all racial/ethnic groups 2015–2021; steepest increases in Black and Asian/Pacific Islander women; N > 2.9 million births.

  • Race-Specific Prevalence of Hidradenitis Suppurativa

    Black patients have a disproportionately high prevalence of hidradenitis suppurativa in the US relative to population share.

  • Patterns and Trends in Age-Specific Black-White Differences in Breast Cancer Incidence and Mortality – United States, 1999–2014

    Black women have a ~40% higher breast cancer mortality rate than White women despite similar or lower incidence — driven by tumor biology, late-stage diagnosis, and treatment access gaps.

  • Hysterectomy Among Women Age 18 and Older: United States, 2021

    Non-Hispanic Black women had the highest hysterectomy prevalence of any racial/ethnic group in the 2021 National Health Interview Survey; non-Hispanic Asian women the lowest.

Your health is not a burden. Your symptoms are not drama. Your body is not broken.

The system failed to account for you , but you can arm yourself with the truth of what is happening in your body and demand care that meets you where you actually are. Keza stands with you in that demand.

Open my Doctor prep